Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.

Abstract: Systems, methods and apparatus are disclosed for providing reduced engine start times for a fumigation type internal combustion engine. A bypass is provided that directly connects the air-fuel mixer upstream of the compressor to the intake manifold, providing the air-fuel mixture to the intake manifold during engine startup.

Abstract: Devices, systems, and methods for predictive anti-lag braking control for autonomous vehicles are described. An example method of controlling a vehicle includes receiving, from a controller, a first plurality of values indicative of a brake wheel torque demand associated with a deceleration profile of the vehicle, deriving, based on the first plurality of values and a steady-state brake model, a second plurality of values indicative of a brake pressure demand, wherein an input to the steady-state brake model comprises the brake pressure demand and at least one previous brake wheel torque demand, and wherein an output of the steady-state brake system comprises a current brake wheel torque demand, generating, based on the second plurality of values and at least the steady-state model, a plurality of brake control commands, and controlling, using the plurality of brake control commands, the air brake system.

Abstract: Devices, systems, and methods for estimating wheel torque in an autonomous vehicle include a method for controlling a vehicle includes using a dual filter framework to generate an updated estimate of a wheel torque, and controlling, based on the updated estimate of the wheel torque, the vehicle. A first filter of the dual filter framework is configured to generate a blended estimate of the wheel torque by combining a first estimate of the wheel torque that is generated based on a set of mechanical torque transfer models of at least a powertrain and a brake of the vehicle and a second estimate of wheel torque that is generated based on an inverted longitudinal dynamic model, and a second non-linear filter of the dual filter framework is configured to generate the updated estimate of a wheel torque and vehicle velocity based on a torque delivery damping process model on vehicle motion.

Abstract: A method of operating an electronic control system of a vehicle includes determining a first braking distance to achieve a first speed of a first vehicle, receiving a second vehicle braking distance to achieve a second vehicle speed of a second vehicle forward of the first vehicle, determining a minimum following distance between the first vehicle and the second vehicle in response to the first braking distance and the second braking distance, and controlling operation of the vehicle with an autonomous control system using the minimum following distance. A computer-implemented fleet management system is configured to receive logistics objectives including load, timeline, and cost information for a freight delivery, receive fleet information including tire parameters of a plurality of vehicles of a fleet, and determine a plurality of trips and a corresponding vehicle selection in response to the logistics objectives and the fleet information.

Abstract: Systems and apparatuses include one or more processing circuits including one or more memory devices coupled to one or more processors. The one or more memory devices are configured to store instructions thereon that, when executed by the one or more processors, cause the one or more processors to: receive a parameter regarding operation of a first vehicle of a first platoon; compare the parameter to a first predetermined threshold; responsive to determining that the parameter satisfies the first predetermined threshold, determine an exit parameter for the first vehicle; and cause the first vehicle to exit the first platoon based on the exit parameter.

Abstract: Systems and apparatuses include one or more processing circuits comprising one or more memory devices coupled to one or more processors, the one or more memory devices configured to store instructions thereon that, when executed by the one or more processors, cause the one or more processors to: determine at least one reason for a deserter to exit a first platoon; determine a deserter position within the first platoon; communicate the deserter exit to the first platoon after determination of the at least one reason for the deserter to exit the first platoon based at least in part on the deserter position; adapt a behavior of the first platoon to allow the deserter to exit the first platoon; and reconfigure the remaining vehicles from the first platoon into a second platoon.

Abstract: Systems and apparatuses include a system including an electronic compressor, a bypass intake coupled between an engine system of a generator set and the electronic compressor, a bypass outlet coupled between the electronic compressor and the engine system, and a valve positioned to selectively inhibit flow between the bypass intake and the bypass outlet during a starting operation.

Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the xanthine dehydrogenase (XDH) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an XDH gene and to methods of treating or preventing an XDH-associated disease in a subject.

Abstract: Systems, methods and apparatus are disclosed for providing reduced engine start times for a fumigation type internal combustion engine. A bypass is provided that directly connects the air-fuel mixer upstream of the compressor to the intake manifold, providing the air-fuel mixture to the intake manifold during engine startup.

Abstract: The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the SERPINF2 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a SERPINF2 gene and to methods of preventing and treating a SERPINF2-associated disorder, e.g., a disorder associated with thrombosis.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the CPB2 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a CPB2 gene and to methods of preventing and treating a CPB2-associated disorder, e.g., a disorder associated with thrombosis.

Abstract: The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the xanthine dehydrogenase (XDH) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an XDH gene and to methods of treating or preventing an XDH-associated disease in a subject.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.

Abstract: Systems and apparatuses include one or more processing circuits comprising one or more memory devices coupled to one or more processors, the one or more memory devices configured to store instructions thereon that, when executed by the one or more processors, cause the one or more processors to: determine at least one reason for a deserter to exit a first platoon; determine a deserter position within the first platoon; communicate the deserter exit to the first platoon after determination of the at least one reason for the deserter to exit the first platoon based at least in part on the deserter position; adapt a behavior of the first platoon to allow the deserter to exit the first platoon; and reconfigure the remaining vehicles from the first platoon into a second platoon.

Abstract: Systems and apparatuses include a controller including a circuit structured to communicate with a platoon of vehicles, determine a platoon rank order, determine final separation distances between vehicles, affect operation of each vehicle to achieve the platoon rank order and final separation distances, monitor the platoon of vehicles to determine if a deserter is leaving the platoon of vehicles or if a critical change has occurred, determine an updated platoon rank order, and determine an updated final separation distances between vehicles.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.

Abstract: The present invention relates to methods of use of RNAi agents, e.g., double stranded RNAi agents, targeting a Factor XII (Hageman Factor (F12) gene, for treating subjects having a contact activation pathway-associated disease, such as a thrombophilia or hereditary angioedema (HAE), methods for preventing at least one symptom in a subject having a contact activation pathway-associated disease, such as a thrombus formation or an angioedema attack, and RNAi agents targeting an F12 gene, for use in the methods of the invention.

Abstract: The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F12) gene, or the Kininogen 1 (KNG1) gene, and methods of using such RNAi agents to inhibit expression of a KLKB1 gene, an F12 gene, and/or a KNG1 gene, and methods of treating subjects having an hereditary angioedema (HAE) and/or a contact activation pathway-associated disorder.